Belfast-based Fusion Antibodies plc (AIM: FAB) announced on Wednesday that it has won three follow-on projects under its collaborative research and development agreement with a US-based biotechnology company.

The contracts build on progress made in the stable Cell Line Development project announced on 27 February 2025.

Valued at approximately USD460,000, the new agreements expand the scope of the original work and add a further engineering project. At least USD400,000 is expected to be recognised in the current financial year ending 31 March 2026.

Fusion specialises in pre-clinical antibody discovery, engineering and supply for therapeutic and diagnostic applications. The company, admitted to AIM in December 2017, has delivered over 250 antibody sequencing and expression projects and more than 200 humanisation projects for a global client base, including eight of the world's ten largest pharmaceutical companies by revenue.